Tubulis
Tubulis develops antibody-drug conjugates (ADCs) with indication-tailored targeting molecules and payloads. Their proprietary platform allows for customizable ADCs with superior properties, addressing key bottlenecks in ADC development. The company focuses on solid tumor indications.
Buy Funded Startups lists
Funding Round: Series B2
Funding Amount: €128M
Date: 14-Mar-2024
Investors: EQT Life Sciences, Nextech Invest Ltd, Frazier Life Sciences, Deep Track Capital, Andera Partners, BioMedPartners, Fund+, Bayern Kapital, Evotec, coparion, Seventure Partners, OCCIDENT, High-Tech Gründerfonds (HTGF)
Markets: Biotechnology, Oncology, Pharmaceuticals, Therapeutics, Life Science, Drug Discovery
HQ: Munich, Bavaria, Germany
Founded: 2012
Website: https://tubulis.com/
LinkedIn: https://www.linkedin.com/company/tubulis/
Twitter: https://twitter.com/tubulis_gmbh
Crunchbase: https://www.crunchbase.com/organization/tubulis-technologies
Leave a Comment
Comments
No comments yet.